- Conditions
- COVID-19
- Interventions
- BAT2020
- Drug
- Lead sponsor
- Bio-Thera Solutions
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Idaho Falls, Idaho
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 6,600
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Interventions
- RT001
- Drug
- Lead sponsor
- Revance Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • San Diego, California • Omaha, Nebraska
- Conditions
- Covid19 Pneumonia
- Interventions
- EC-18, Placebo
- Drug
- Lead sponsor
- Enzychem Lifesciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Warwick, Rhode Island
- Conditions
- Hyperpigmentation, Photodamaged Skin, Wrinkle, Fine Lines
- Interventions
- Gentle Cleansing Lotion, Revision Skincare
- Other
- Lead sponsor
- Revision Skincare
- Industry
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Solana Beach, California • Greenwood Village, Colorado • Nashville, Tennessee
- Conditions
- Blepharitis
- Interventions
- AzaSite®
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 2
- States / cities
- Lewiston, Maine • Andover, Massachusetts
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Not listed
- Enrollment
- 1,860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Duarte, California • Oakland, California + 33 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Ketotifen/naphazoline, Ketotifen, Naphazoline, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- North Andover, Massachusetts
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- ABT-874
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 80 more
- Conditions
- Hypertension
- Interventions
- Aliskiren, Hydrochlorothiazide
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Myopia
- Interventions
- comfilcon A, samfilcon A
- Device
- Lead sponsor
- CooperVision, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Whittier, California • Medina, Minnesota
- Conditions
- Cardiac Arrhythmias
- Interventions
- EluPro Antibiotic-Eluting BioEnvelope
- Combination Product
- Lead sponsor
- Elutia Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- La Jolla, California • Tallahassee, Florida • Boston, Massachusetts + 1 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
- Interventions
- GRN1005
- Drug
- Lead sponsor
- Angiochem Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 9
- States / cities
- La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more
- Conditions
- Foot Fusion
- Interventions
- Augment® Bone Graft, Standard of Care
- Device · Procedure
- Lead sponsor
- BioMimetic Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • San Francisco, California • Santa Cruz, California + 27 more
- Conditions
- Hodgkin's Lymphoma
- Interventions
- R-mabHDI and ABVD, ABVD
- Drug
- Lead sponsor
- American Scitech International
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- East Brunswick, New Jersey
- Conditions
- ALS, Amyotrophic Lateral Sclerosis
- Interventions
- Fosigotifator, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Irvine, California • Los Angeles, California • San Francisco, California + 4 more
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Redwood City, California • Atlanta, Georgia + 5 more
- Conditions
- Lumbar Degenerative Disc Disease
- Interventions
- SB-01 For Injection, Sham Needle
- Drug
- Lead sponsor
- Spine BioPharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Rituximab, BI 695500
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 13
- States / cities
- Muscle Shoals, Alabama • Bakersfield, California • Burbank, California + 10 more
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma, Waldenstrom Macroglobulinemia, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Lymphoma, Childhood Myelodysplastic Syndrome, Stage II Contiguous Adult Burkitt Lymphoma, Stage II Contiguous Adult Diffuse Large Cell Lymphoma, Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma, Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma, Stage II Adult Contiguous Immunoblastic Lymphoma, Stage II Contiguous Adult Lymphoblastic Lymphoma, Stage II Grade 1 Contiguous Follicular Lymphoma, Stage II Grade 2 Contiguous Follicular Lymphoma, Stage II Grade 3 Contiguous Follicular Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Adult Burkitt Lymphoma, Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma, Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma, Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma, Stage II Adult Non-Contiguous Immunoblastic Lymphoma, Stage II Non-Contiguous Adult Lymphoblastic Lymphoma, Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage II Small Lymphocytic Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Burkitt Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Myelodysplastic Syndrome, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Immunoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Childhood Burkitt Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage II Childhood Burkitt Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Childhood Burkitt Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Burkitt Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
- Interventions
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Sirolimus
- Drug · Radiation · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Atlanta, Georgia • Salt Lake City, Utah + 2 more
- Conditions
- Dry Eye Syndrome
- Interventions
- BRM421, Placebo
- Drug
- Lead sponsor
- BRIM Biotechnology Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Lewiston, Maine • Andover, Massachusetts
- Conditions
- Leukemia, T-Cell
- Interventions
- forodesine hydrochloride (BCX-1777)
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Palo Alto, California • Denver, Colorado + 18 more
- Conditions
- Diabetic Foot Ulcer
- Interventions
- OptiPulse™, Standard of Care offloading device
- Device
- Lead sponsor
- Compedica Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Los Angeles, California • Vista, California + 12 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- APG-1252, Paclitaxel
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Plantation, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
- Conditions
- Cancer
- Interventions
- docetaxel, thalidomide
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio